Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 23;4(1-2):21-29.
doi: 10.1007/s44228-022-00007-5. eCollection 2022 Jun.

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia

Obada Ababneh  1 , Hassan Abushukair  1 , Aref Qarqash  1 , Sebawe Syaj  1 , Samer Al Hadidi  2
Affiliations
Review

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia

Obada Ababneh et al. Clin Hematol Int. .

Abstract

The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström's Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clinical outcomes and/or safety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM in front-line and refractory or relapsed settings. We also highlight common adverse events, the emergence of BTK inhibitors resistance, and future directions of their use.

Keywords: Bruton tyrosine kinase inhibitors; Ibrutinib; Waldenstrom’s Macroglobulinemia; Zanubrutinib.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015;169(1):81–89. doi: 10.1111/bjh.13264. - DOI - PubMed
    1. Jeong S, Kong SG, Kim DJ, Lee S, Lee HS. Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study. BMC Cancer. 2020;20(1):623. doi: 10.1186/s12885-020-07120-9. - DOI - PMC - PubMed
    1. Yin X, Chen L, Fan F, Yan H, Zhang Y, Huang Z, et al. Trends in incidence and mortality of Waldenström macroglobulinemia: a population-based study. Front Oncol. 2020;10:1712. doi: 10.3389/fonc.2020.01712. - DOI - PMC - PubMed
    1. Pophali PA, Bartley A, Kapoor P, Gonsalves WI, Ashrani AA, Marshall AL, et al. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014–1017. doi: 10.1111/bjh.15201. - DOI - PubMed
    1. Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, et al. Progression in smoldering Waldenström macroglobulinemia: long-term results. Blood. 2012;119(19):4462–4466. doi: 10.1182/blood-2011-10-384768. - DOI - PMC - PubMed

LinkOut - more resources